Miracle Mile Advisors LLC Has $341,000 Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Miracle Mile Advisors LLC boosted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 3.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,984 shares of the medical equipment provider’s stock after buying an additional 185 shares during the period. Miracle Mile Advisors LLC’s holdings in Boston Scientific were worth $341,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of BSX. Breakwater Capital Group lifted its position in shares of Boston Scientific by 4.3% in the first quarter. Breakwater Capital Group now owns 7,289 shares of the medical equipment provider’s stock worth $499,000 after purchasing an additional 303 shares in the last quarter. New Mexico Educational Retirement Board lifted its position in Boston Scientific by 10.8% in the 1st quarter. New Mexico Educational Retirement Board now owns 82,862 shares of the medical equipment provider’s stock worth $5,675,000 after buying an additional 8,100 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Boston Scientific by 15.8% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 77,216 shares of the medical equipment provider’s stock valued at $5,289,000 after buying an additional 10,532 shares during the period. AMF Tjanstepension AB grew its holdings in shares of Boston Scientific by 2.2% during the 1st quarter. AMF Tjanstepension AB now owns 854,223 shares of the medical equipment provider’s stock valued at $58,506,000 after acquiring an additional 18,320 shares in the last quarter. Finally, Courier Capital LLC increased its stake in shares of Boston Scientific by 22.5% in the first quarter. Courier Capital LLC now owns 11,399 shares of the medical equipment provider’s stock worth $781,000 after acquiring an additional 2,096 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $75.33, for a total transaction of $526,029.39. Following the sale, the executive vice president now directly owns 45,628 shares of the company’s stock, valued at $3,437,157.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Boston Scientific news, Director Edward J. Ludwig sold 9,818 shares of the business’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $73.29, for a total value of $719,561.22. Following the transaction, the director now directly owns 41,374 shares in the company, valued at $3,032,300.46. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $75.33, for a total transaction of $526,029.39. Following the sale, the executive vice president now directly owns 45,628 shares of the company’s stock, valued at approximately $3,437,157.24. The disclosure for this sale can be found here. Insiders sold 65,276 shares of company stock valued at $4,804,228 over the last quarter. Corporate insiders own 0.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on BSX shares. Barclays lifted their price objective on Boston Scientific from $70.00 to $78.00 and gave the company an “overweight” rating in a research report on Friday, April 26th. The Goldman Sachs Group began coverage on Boston Scientific in a research note on Thursday, May 30th. They issued a “buy” rating and a $90.00 price target for the company. UBS Group raised their price objective on shares of Boston Scientific from $74.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Robert W. Baird boosted their target price on shares of Boston Scientific from $79.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday, April 25th. Finally, Needham & Company LLC restated a “buy” rating and set a $82.00 price target on shares of Boston Scientific in a report on Tuesday, June 18th. Three equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $77.27.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $76.41 on Tuesday. The business’s 50 day moving average is $74.84 and its 200-day moving average is $67.67. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $112.10 billion, a PE ratio of 64.21, a PEG ratio of 2.65 and a beta of 0.78. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $77.99.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.51 by $0.05. The firm had revenue of $3.86 billion for the quarter, compared to analyst estimates of $3.68 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. Sell-side analysts predict that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.